Back to top
more

Bellerophon Therapeutics (BLPH)

(Delayed Data from OTC)

$0.06 USD

0.06
842

0.00 (0.00%)

Updated Apr 30, 2024 11:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BLPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Bellerophon Therapeutics, Inc. [BLPH]

Reports for Purchase

Showing records 21 - 37 ( 37 total )

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

12/18/2019

Company Report

Pages: 6

Phase 2/3 INOpulse Cohort 2 Topline Data Supportive of Phase 3 Initiation Planned for 2020; Reit Buy and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

08/09/2019

Company Report

Pages: 4

Upcoming Cohort 2 Data Can Offer Incremental Clarity Into Pivotal Studies

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

08/06/2019

Company Report

Pages: 37

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

05/30/2019

Daily Note

Pages: 5

Lung Disease KOL Offers Insights Into Actigraphy, Emergent Patient Activity Metric; Reit Buy and $3PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

05/10/2019

Company Report

Pages: 5

Full Steam Ahead With PH-ILD Program; Reit Buy and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

04/09/2019

Daily Note

Pages: 4

Regulatory Clarity Positions INOpulse Well as Potential First Approved Therapy for PH-ILD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

01/29/2019

Daily Note

Pages: 4

Positive INOpulse Phase 2b Interim Data Supports Actigraphy as Clinical Endpoint

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

11/09/2018

Company Report

Pages: 6

Looking Forward to Next Data Read Out in 2019

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

08/09/2018

Company Report

Pages: 5

INOpulse Future Rests on Shift to ILD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

08/02/2018

Company Report

Pages: 5

Remain Bullish Ahead of Impending Interim Phase 3 PAH Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

05/11/2018

Company Report

Pages: 5

All Eyes Remain on INOvation-1; Reit Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

03/20/2018

Company Report

Pages: 5

Looking Ahead to Data Catalysts This Year; Reit Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

09/06/2017

Daily Note

Pages: 3

PH-COPD Top Line Builds Upon INOpulse’s Clinical Potential: Reit Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

08/10/2017

Company Report

Pages: 6

We Believe KOL Focus on PH-ILD Signals Right Strategy Going Forward: Reit Buy Rating and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

05/24/2017

Daily Note

Pages: 4

Takeaways from IPF and COPD Posters: V/Q Mismatch Prevention and Composite Endpoint May Suggest Long-Term Benefit

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

02/02/2017

Daily Note

Pages: 3

Preview of Phase 2 PH-COPD and PH-IPF on Tap for Early 2017

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Bellerophon Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

01/20/2017

Company Report

Pages: 19

The Power of NO for PAH: Initiating with Buy Rating and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 50.00

Research Provided by a Third Party